(19)
(11) EP 2 398 458 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
30.10.2013 Bulletin 2013/44

(45) Mention of the grant of the patent:
17.07.2013 Bulletin 2013/29

(21) Application number: 10711743.4

(22) Date of filing: 19.02.2010
(51) International Patent Classification (IPC): 
A61K 9/00(2006.01)
A61K 33/38(2006.01)
 A61K 31/716(2006.01)
A61K 45/06(2006.01)
(86) International application number:
PCT/IT2010/000064
(87) International publication number:
WO 2010/095158 (26.08.2010 Gazette 2010/34)

(54)

PHARMACEUTICAL COMPOSITION CONTAINING MICROCOLLOIDAL SILVER AND CARBOXYMETHYL BETA GLUCAN FOR DISINFECTION OF THE NASAL MUCOSAE

PHARMAZEUTISCHE ZUSAMMENSETZUNG MIT MIKROKOLLOIDALEM SILBER UND CARBOXYMETHYL-BETA-GLUCAN ZUR DESINFEKTION DER NASENSCHLEIMHAUT

COMPOSITION PHARMACEUTIQUE À BASE D'ARGENT MICRO-COLLOÏDAL ET DE BÊTA-GLYCANE DE CARBOXY-MÉTHYLE DESTINÉ À LA DÉSINFECTION DES MUQUEUSES NASALES

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR
Designated Extension States:
AL BA RS

(30) Priority: 20.02.2009 IT RM20090077

(43) Date of publication of application:
28.12.2011 Bulletin 2011/52

(73) Proprietor: D.M.G. Italia Srl
00040 Pomezia (RM) (IT)

(72) Inventor:
  • MERCURI Luigi
    1-00040 Pomezia (RM) (IT)

(74) Representative: Sarpi, Maurizio 
Studio Ferrario S.r.l. Via Collina, 36
00187 Roma
00187 Roma (IT)


(56) References cited: : 
US-A1- 2006 122 082
US-B1- 6 454 754
 US-A1- 2008 020 060
   
  • KUBALA L ET AL: "The effect of (1->3)-beta-d-glucans, carboxymethylglucan and schizophyllan on human leukocytes in vitro" CARBOHYDRATE RESEARCH, ELSEVIER SCIENTIFIC PUBLISHING COMPANY. AMSTERDAM, NL, vol. 338, no. 24, 21 November 2003 (2003-11-21), pages 2835-2840, XP004479501 ISSN: 0008-6215
  • CHEN ET AL: "Nanosilver: A nanoproduct in medical application" TOXICOLOGY LETTERS, ELSEVIER BIOMEDICAL PRESS, AMSTERDAM, NL, vol. 176, no. 1, 16 October 2007 (2007-10-16), pages 1-12, XP022390861 ISSN: 0378-4274
 
Remarks:
The file contains technical information submitted after the application was filed and not included in this specification
 
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).